SPP1 and COVID-19: Our study revealed that SPP1, at the concentration detected in the post–COVID-19 stage, induced some of the features of proinflammatory CD14+ monocytes — for example, an increase in alarmins (S100A12 and S100A9) and a decrease in MHCII molecules.